行情

MACK

MACK

Merrimack Pharma
NASDAQ

实时行情|Nasdaq Last Sale

4.120
-0.130
-3.06%
交易中 12:48 11/14 EST
开盘
4.260
昨收
4.250
最高
4.340
最低
4.120
成交量
4,849
成交额
--
52周最高
6.19
52周最低
2.909
市值
5,505.56万
市盈率(TTM)
-1.2215
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MACK 新闻

  • Proxy fights reach 'frightening' level in life sciences, other industries, top attorney says
  • American City Business Journals.10/28 11:04
  • 锁定磋商成果,中美向阶段性协议再近一步
  • 央视.10/27 22:25
  • 网易有道上市之后
  • 新浪财经综合.10/27 21:48
  • SpaceX:将在之后三年左右实现“星舰”载人着陆月球
  • 新浪美股.10/27 21:32

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
-0.52%

热门股票

名称
价格
涨跌幅

MACK 简况

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.
展开

Webull提供Merrimack Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。